Celldex Therapeutics, Inc. (NASDAQ:CLDX) had its price target reduced by Jefferies Group LLC from $5.00 to $4.00 in a research note published on Wednesday morning. Jefferies Group LLC currently has a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on CLDX. Zacks Investment Research lowered Celldex Therapeutics from a buy rating to a hold rating in a report on Wednesday, November 16th. HC Wainwright reaffirmed a buy rating and issued a $6.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, March 15th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $7.63.

Celldex Therapeutics (NASDAQ:CLDX) opened at 3.37 on Wednesday. The firm’s 50 day moving average price is $3.43 and its 200-day moving average price is $3.66. Celldex Therapeutics has a one year low of $2.85 and a one year high of $5.13. The company’s market capitalization is $415.23 million.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/jefferies-group-llc-cuts-celldex-therapeutics-inc-cldx-price-target-to-4-00-2.html

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The business had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.10 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.33) EPS. Equities analysts forecast that Celldex Therapeutics will post ($1.23) earnings per share for the current fiscal year.

Your IP Address:

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in shares of Celldex Therapeutics by 31.1% in the third quarter. BNP Paribas Arbitrage SA now owns 147,084 shares of the biopharmaceutical company’s stock worth $594,000 after buying an additional 34,851 shares in the last quarter. Creative Planning raised its position in shares of Celldex Therapeutics by 971.4% in the third quarter. Creative Planning now owns 55,346 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 50,180 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new position in shares of Celldex Therapeutics during the third quarter worth approximately $150,000. Wells Fargo & Company MN raised its position in shares of Celldex Therapeutics by 31.2% in the third quarter. Wells Fargo & Company MN now owns 78,383 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 18,661 shares in the last quarter. Finally, Marcus Capital LLC raised its position in shares of Celldex Therapeutics by 0.5% in the third quarter. Marcus Capital LLC now owns 112,200 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 600 shares in the last quarter. 55.99% of the stock is currently owned by hedge funds and other institutional investors.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

5 Day Chart for NASDAQ:CLDX

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.